The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL)

被引：0
|
作者：
Bernasconi, E. [1 ]
Gaudio, E. [1 ]
Lejeune, P. [2 ]
Tarantelli, C. [1 ]
Rinaldi, A. [1 ]
Kwee, I. [1 ]
Mensah, A. A. [1 ]
Chung, E. Y. L. [1 ]
Stathis, A. [3 ]
Ocker, M. [2 ]
Zucca, E. [3 ]
Haendler, B. [2 ]
Bertoni, F. [1 ]
机构：
[1] Inst Oncol Res IOR, Lymphoma & Genom Res Program, Bellinzona, Switzerland
[2] Bayer Pharma AG, Global Drug Discovery, GTRG Oncol, Berlin, Germany
[3] IOSI Oncol Inst Southern Switzerland, Div Res, Bellinzona, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32846-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
251
引用
收藏
页码：S84 / S84
页数：1
相关论文
共 50 条
  • [1] The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL)
    Bonetti, P.
    Ponzoni, M.
    Tibiletti, M. G.
    Stathis, A.
    Heirat, P.
    Zucca, E.
    Bertoni, F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 163 - 163
  • [2] BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma
    Cascione, Luciano
    Gaudio, Eugenio
    Bernasconi, Elena
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Bomben, Riccardo
    Gattei, Valter
    Kwee, Ivo
    Stathis, Anastasios
    Riveiro, Maria Eugenia
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. BLOOD, 2014, 124 (21)
  • [3] Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma
    Recasens-Zorzo, Clara
    Cardesa-Salzmann, Teresa
    Petazzi, Paolo
    Ros-Blanco, Laia
    Esteve-Arenys, Anna
    Clot, Guillem
    Guerrero-Hernandez, Martina
    Rodriguez, Vanina
    Soldini, Davide
    Valera, Alexandra
    Moros, Alexandra
    Climent, Fina
    Gonzalez-Barca, Eva
    Mercadal, Santiago
    Arenillas, Leonor
    Calvo, Xavier
    Mate, Jose Luis
    Gutierrez-Garcia, Gonzalo
    Casanova, Isolda
    Mangues, Ramon
    Sanjuan-Pla, Alejandra
    Bueno, Clara
    Menendez, Pablo
    Martinez, Antonio
    Colomer, Dolors
    Estrada Tejedor, Roger
    Teixido, Jordi
    Campo, Elias
    Lopez-Guillermo, Armando
    Ignacio Borrell, Jose
    Colomo, Luis
    Perez-Galan, Patricia
    Roue, Gael
    [J]. HAEMATOLOGICA, 2019, 104 (04) : 778 - 788
  • [4] Combinations containing the aza-anthracenedione pixantrone show pre-clinical activity in diffuse large B-cell lymphoma (DLBCL)
    Tarantelli, C.
    Gaudio, E.
    Kwee, I.
    Stathis, A.
    Zintl, P.
    Turton, M.
    Zucca, E.
    Bertoni, F.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 74 - 74
  • [5] Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)
    Mavis, Cory
    Torka, Pallawi
    Zeccola, Alison
    Patel, Priyank P.
    Gu, Juan
    Barth, Matthew J.
    Hernandez-Ilizaliturri, Francisco J.
    [J]. BLOOD, 2017, 130
  • [6] Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)
    Patel, Priyank P.
    Zeccola, Alison
    Neppalli, Vishala T.
    Gu, Juan J.
    Mavis, Cory
    Sait, Sheila
    Hernandez-Ilizaliturri, Francisco J.
    [J]. BLOOD, 2015, 126 (23)
  • [7] The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL)
    Gaudio, Eugenio
    Cascione, Luciano
    Ponzoni, Maurilio
    Tarantelli, Chiara
    Bernasconi, Elena
    Riveiro, Maria Eugenia
    Cvitkovic, Esteban
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. BLOOD, 2015, 126 (23)
  • [8] Immune-mediated antitumor activity with a clinical stage BET bromodomain inhibitor ODM-207 in pre-clinical models
    Deshpande, Pratima
    Babu, Ravi Krishna
    Vadnal, Prashant Yallappa
    Jaleel, Mahaboobi
    Ramachandra, Murali
    Abbineni, Chandrasekhar
    Samajdar, Susanta
    Moilanen, Anu-Maarit
    Kallio, Pekka
    [J]. CANCER RESEARCH, 2017, 77
  • [9] The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors
    Gaudio, Eugenio
    Bernasconi, Elena
    Kwee, Ivo
    Boi, Michela
    Bonetti, Paola
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Ponzoni, Maurilio
    Stathis, Anastasios
    Stuessi, Georg
    Riveiro, Eugenia
    Herait, Patrice
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [10] Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma
    Recasens-Zorzo, Clara
    Cardesa-Salzmann, Teresa
    Ros-Blanco, Laia
    Esteve-Arenys, Anna
    Clot, Guillem
    Guerrero-Hernandez, Martina
    Valera, Alejandra
    Moros, Alejandra
    Gutierrez, Gonzalo
    Casanova, Isolda
    Mangues, Ramon
    Sanjuan, Alejandra
    Menendez, Pablo
    Rodriguez, Vanina
    Martinez, Antonio
    Jares, Pedro
    Colomer, Dolors
    Teixido, Jordi
    Borrell, Jose Ignacio
    Campo, Elias
    Lopez-Guillermo, Armando
    Colomo, Luis
    Perez-Galan, Patricia
    Roue, Gael
    [J]. CANCER RESEARCH, 2017, 77
12345